Astellas gets Japanese rights to Ilypsa's ILY101
Astellas Pharma has licensed exclusive Japanese development and marketing rights to Ilypsa's (formerly Symyx Therapeutics; next-generation renal therapeutics) ILY101, which has just completed Phase I trials in the US for hyperphosphatemia.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com